Health Canada Adds Submission Class Data to Drug Review Tracker

Health Canada has enhanced its public drug review tracker with new submission class information as of March 20, 2026, providing Canadians with more detailed transparency about pharmaceutical applications under review.

Enhanced Tracking System

The updated Drug and Health Product Submissions Under Review (SUR) system now displays submission class data alongside existing information about drug applications. This enhancement allows the public to better understand the type and category of pharmaceutical submissions being evaluated by Health Canada regulators.

The tracker previously showed basic submission information but now includes classification details that help distinguish between different types of drug applications, including new drug submissions, generic applications, and supplemental filings.

Impact on Generic Medication Transparency

The timing of this enhancement coincides with increased public interest in generic medication approvals, particularly for high-profile drugs like Ozempic and Wegovy. The enhanced tracker provides clearer visibility into which submissions represent generic versions versus brand-name applications.

Health Canada currently lists nine generic semaglutide applications under review, and the new classification system helps distinguish these from other types of pharmaceutical submissions. The agency maintains its 180-day target review timeline for standard submissions, though complex applications may require additional time.

Generic Application Status

The enhanced tracker shows various pharmaceutical companies have submitted applications for generic versions of popular medications. Known applicants include established generic manufacturers such as:

• Sandoz Canada
• Apotex Inc.
• Teva Canada Limited
• Taro Pharmaceuticals

Canadian company Vimy Pharma has also indicated plans to submit a generic semaglutide application, which would appear on the updated tracking system once filed.

Regulatory Timeline Considerations

The March 20, 2026 update date represents the most recent enhancement to the submission tracking system. Health Canada reviews applications on a first-come, first-served basis within each priority category, with the enhanced tracker now showing submission class to help stakeholders understand application types.

For medications like Mounjaro, the tracker provides visibility into both brand-name supplemental applications and potential generic submissions. Canadians can use the generic semaglutide tracker to monitor specific developments in generic approvals.

Public Access and Information

The enhanced submission tracker is available on Health Canada's website and updates regularly as new applications are received and existing ones progress through the review process. The system provides submission dates, target completion dates, and now includes the submission class information added in the March update.

Healthcare professionals and patients can access this information to better understand the pharmaceutical approval pipeline. For questions about specific medications or coverage, Canadians can consult the insurance coverage checker or review the FAQ section for additional guidance.

This article is for informational purposes only and does not constitute medical advice.